Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study
After adjusting for baseline clinical factors, we found that omission of the 5-FU bolus from FOLFOX, FOLFIRI, and FOLFIRINOX regimens was not associated with decreased survival, but resulted in decreased toxicity and possible health care savings.
Authors
- Daniel Becker (ORCID: https://orcid.org/0000-0001-7230-8432)
- Paul E. Oberstein (ORCID: https://orcid.org/0000-0001-5918-6004)
- Michael Shusterman (ORCID: https://orcid.org/0000-0003-2899-7714)
- Shun Yu (ORCID: https://orcid.org/0000-0003-0721-5429)
- Jordan Berlin (ORCID: https://orcid.org/0000-0001-7571-2385)
- Ben Boursi (ORCID: https://orcid.org/0000-0002-1304-8340)
- Anil B. Nagar (ORCID: https://orcid.org/0000-0003-4946-209X)
- Saad Saffo (ORCID: https://orcid.org/0000-0001-5375-3100)
- Charlene Thomas (ORCID: https://orcid.org/0000-0002-7685-0090)
- Chengwei Peng (ORCID: https://orcid.org/0000-0002-9890-4926)
- Lawrence P. Leichman
Institutions
- Northwestern University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Sheba Medical Center (IL)
- Yale University (US)
- Weill Cornell Medicine (US)
- Vanderbilt-Ingram Cancer Center
- New York University (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2024-09-05
- DOI
- https://doi.org/10.6004/jnccn.2024.7029
- Citations
- 7
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.98